175
Participants
Start Date
October 25, 2023
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
Miricorilant (Cohort A)
Miricorilant 100 mg for oral dosing
Placebo (Cohort A)
Matching placebo for oral dosing for 48 Weeks
Miricorilant (Cohort B)
Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing
Placebo (Cohort B)
Matching placebo for oral dosing for 24 Weeks
Site #454, New York
Site #445, East Syracuse
Site #463, Manassas
Site #440, Rockville
Site #464, Morehead City
Site # 101, Gainesville
Site #460, Viera
Site #465, Hallandale
Site #430, Hialeah Gardens
Site #438, Miami Lakes
Site #452, Boca Raton
Site #475, Largo
Site #458, Lakewood Rch
Site #461, Cordova
Site #470, Columbus
Site #437, Westlake
Site #448, Dayton
Site #447, Beavercreek
Site #442, Saint Paul
Site #228, Kansas City
Site #061, Metairie
Site #451, Marrero
Site #453, Houma
Site #370, Dallas
Site # 546, Arlington
Site # 066, Houston
Site #305, Houston
Site #459, Katy
Site #433, San Antonio
Site #434, Waco
Site #212, San Antonio
Site #432, Brownsville
Site #213, Edinburg
Site #215, Edinburg
Site #431, Georgetown
Site #545, Austin
Site #211, Austin
Site #441, West Jordan
Site #207, Chandler
Site #209, Tucson
Site #373, Los Angeles
Site #378, Huntington Park
Site #469, Long Beach
Site #214, Panorama City
Site #233, Santa Ana
Site #439, Lancaster
Site #226, Seattle
Site #482, New Delhi
Site #510, New Delhi
Site #501, New Delhi
Site # 494, Rohtak
Site #495, Ludhiana
Site #488, Varanasi
Site #503, Varanasi
Site #549, Lucknow
Site #504, Dehradun
Site #489, Jaipur
Site # 485, Jaipur
Site #513, Rajkot
Site #492, Ahmedabad
Site #502, Vadodara
Site #490, Surat
Site #514, Surat
Site #512, Mumbai
Site #509, Mumbai
Site #496, Pune
Site #500, Nagpur
Site #486, Hyderabad
Site #511, Mysore
Site #508, Madurai
Site #507, Thiruvananthapuram
Site #487, Kolkata
Site #493, Kolkata
Site #491, Kolkata
Site #506, Guwahati
Site #455, Jackson
Site #457, San Juan
Lead Sponsor
Corcept Therapeutics
INDUSTRY